| 货号 | MAB91241-SP |
| 别名 | Iboctadekin; IFN-gamma-inducing factor; IGIF; IGIFIL-1 gamma; IL-18MGC12320; IL-1F4; IL1F4iboctadekin; IL-1g; Interferon gamma-inducing factor; interleukin 18 (interferon-gamma-inducing factor); Interleukin-1 gamma; interleukin-18 | 全称 | Interleukin 18 |
| 应用 | Neutralization |
| 目标/特异性 | Detects human IL-18/IL-1F4 in direct ELISAs. |
| 使用方法 | Neutralization: Measured by its ability to neutralize IL‑18/IL‑1F4-induced IFN‑ gamma secretion in the KG‑1 human acute myelogenous leukemia cell line. Novick, D. et al. (1999) Immunity 10(1):127. The Neutralization Dose (ND50) is typically 3‑15 µg/mL in the presence of 10 ng/mL Recombinant Human IL‑18/IL‑1F4 and 20 ng/mL Recombinant Human TNF‑ alpha. |
| 来源 | Monoclonal Mouse IgG2A Clone # 914205 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 3606 (Human); 16173 (Mouse); 29197 (Rat); 397057 (Porcine); 574151 (Primate) |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | Human IL-18/IL-1F4 synthetic peptide Accession # Q14116 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | Interleukin-18 (IL-18) is a proinflammatory cytokine in the IL-1 family that exerts distinct immune effects depending on the local cytokine environment. It is expressed as a 24 kDa precursor by endothelial and epithelial cells, keratinocytes, gamma δ T cells, and phagocytes. The precursor is activated intracellularly by Caspase-1 mediated proteolysis to release the 17 kDa mature cytokine. The precursor can also be released by necrotic cells for extracellular cleavage by multiple proteases. IL-18 activation is induced by infection or tissue damage and contributes to disease pathology in chronic inflammation (1-3). IL-18 binds to the widely expressed IL-18 R alpha which recruits IL-18 R beta to form the signaling receptor complex (4, 5). Its bioactivity is negatively regulated by interactions with IL-18 binding proteins and virally encoded IL-18BP homologs (6). In the presence of IL-12 or IL-15, IL-18 enhances anti-viral Th1 immune responses by inducing IFN-gamma production and the cytolytic activity of CD8+ T cells and NK cells (7, 8). In the absence of IL-12 or IL-15, however, IL-18 promotes production of the Th2 cytokines IL-4 and IL-13 by CD4+ T cells and basophils (9, 10). In the presence of IL-1 beta or IL-23, IL-18 induces the antigen-independent production of IL-17 by gamma δ T cells and CD4+ T cells (11). IL-18 also promotes myeloid dendritic cell maturation and triggers neutrophil respiratory burst (12, 13). In cancer, IL-18 exhibits diverse activities including enhancing anti-tumor immunity, inhibiting or promoting angiogenesis, and promoting tumor cell metastasis (14). Mature human IL-18 shares approximately 63% amino acid sequence identity with mouse and rat IL-18 (15). Alternative splicing in human ovarian cancer generates an isoform that is resistant to Caspase-1 activation (16). A cell surface form can be expressed on M-CSF induced macrophages and released in response to bacterial endotoxin (17). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
IFN-gamma Secretion Induced by IL-18/IL-1F4 and Neutralization by Human IL-18/IL-1F4 Antibody. In the presence of Recombinant Human TNF-alpha (20 ng/mL, Catalog # 210-TA), Recombinant Human IL-18/IL-1F4 (Catalog # 9124-IL) stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (orange line), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50). Under these conditions, IFN-gamma secretion elicited by Recombinant HumanIL-18/IL-1F4 (10 ng/mL) is neutralized (green line) by increasing concentrations of Rabbit Anti-Human IL-18/IL-1F4 Monoclonal Antibody (Catalog # MAB91241). The ND50 is typically 3-15 µg/mL. |
